Tarsons Products Fair Value
Tarsons Products (TARSONS) average fair value is ₹503.99 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹306.1 (+64.65%), fair value range ₹15.06–₹1688.52. Read Tarsons Products dividend payments for the complete payout history and dividend yield track record.
Fair Value Analysis Export
TARSONS Fair Value vs Current Price — Valuation Summary
TARSONS average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Browse TARSONS financial statements for revenue, profit, balance sheet and cash flow data.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
TARSONS Fair Value Analysis — Data Sources & Coverage
Tarsons Products financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit TARSONS share price screener.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
TARSONS vs Healthcare Sector Peers — P/E, P/B & Market Cap
Tarsons Products P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Aurobindo Pharma | AUROPHARMA | 25.88 | 2.53 | ₹96,652 |
| Sat Kartar Life | SATKARTAR | 13.37 | 3.34 | ₹226 |
| Emcure Pharmaceuticals | EMCURE | 36.8 | 7.52 | ₹37,799 |
| Syngene International | SYNGENE | 69.95 | 3.2 | ₹15,307 |
| Divis Laboratories | DIVISLAB | 85.36 | 14.9 | ₹247,470 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.